Literature DB >> 2029799

Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

P S Banerjee1, J R Robinson.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 2029799     DOI： 10.2165/00003088-199120010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  84 in total

1.  Food-induced gastric retention and absorption of sustained-release procainamide.

Authors:  M L Rocci; P Mojaverian; R J Davis; R K Ferguson; P H Vlasses
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

2.  Pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administration of different doses of transdermal nicotine systems.

Authors:  J P Dubois; A Sioufi; P Müller; D Mauli; P R Imhof
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-03

3.  Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations.

Authors:  P T Pollak; D J Freeman; S G Carruthers
Journal:  J Pharm Sci       Date:  1988-06       Impact factor: 3.534

4.  Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.

Authors:  A Gordin; P Pohto; S Sundberg; S Nykänen; H Haataja; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  The application of stable isotopes to studies of drug bioavailability and bioequivalence.

Authors:  R L Wolen
Journal:  J Clin Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.126

6.  An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.

Authors:  A Gerardin; D Wantiez; A Jaouen
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

7.  The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.

Authors:  M R Gregg; D B Jack; S R Smith; M J Kendall
Journal:  J Clin Pharm Ther       Date:  1987-04       Impact factor: 2.512

8.  Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur.

Authors:  M H Smolensky; P H Scott; W G Kramer
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

9.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 10.  Food interactions with sustained-release theophylline preparations. A review.

Authors:  J H Jonkman
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447
View more
  6 in total

1.  The influence of frusemide formulation on diuretic effect and efficiency.

Authors:  M Wakelkamp; A Blechert; M Eriksson; K Gjellan; C Graffner
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.

Authors:  A Gendron; G Sirois; N P Nair; D Bloom; G Movin-Osswald; G Uppfeldt
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

3.  The influence of drug input rate on the development of tolerance to frusemide.

Authors:  M Wakelkamp; G Alván; H Scheinin; J Gabrielsson
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 4.  Influence of drug formulation on drug concentration-effect relationships.

Authors:  G Castañeda-Hernández; G Caillé; P du Souich
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 5.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

6.  Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.

Authors:  Maria Rosa Ballester; Eulàlia Roig; Ignasi Gich; Montse Puntes; Joaquín Delgadillo; Benjamín Santos; Rosa Maria Antonijoan
Journal:  Drug Des Devel Ther       Date:  2015-08-05       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.